The effectiveness of chloroquine or sulfadoxine-pyrimethamine administered with artesunate for treating uncomplicated falciparum malaria was assessed in 2 Vietnamese provinces where the sensitivity of parasites in vitro to conventional therapies had increased with the removal of drug pressure. In the province of Dac Lac, where potential malaria exposure begins at birth, 57 subjects (mean age, 9.6 years) were randomized to receive artesunate-chloroquine (group 1) or artesunate-sulfadoxine-pyrimethamine (group 2). In the province of Binh Phuoc, 66 nonimmune workers and their relatives (mean age, 24.2 years) were similarly randomized. By day 28 of follow-up, 196% of Dac Lac patients and !52% of Binh Phuoc patients in group 1 and group 2 had an in vivo response that demonstrated sensitivity to therapy. PCR-confirmed cure rates paralleled in vivo results among patients in Binh Phuoc, but PCR results identified 9 (15.7%) of the Dac Lac patients as having experienced asymptomatic, submicroscopic recrudescences. In Dac Lac, pfcrt K76T was near fixation, but infection with parasites with this mutation predicted recrudescence among group 1 patients in Binh Phuoc. Common pfdhfr mutations did not predict outcome in group 2. The successful reintroduction of conventional therapies in combination with artesunate depends on epidemiological and/or parasitological factors.
nations are recommended [2] . An effective, inexpensive, and safe partner-drug with a relatively long halflife would be ideal, but conventional antimalarial compounds do not fulfil these requirements [3] .
Chloroquine-resistant P. falciparum was first found in Vietnam in 1961, and resistance to chloroquine and sulfadoxine-pyrimethamine therapy in vivo ranged from 30% to 85% in the south of the country in the late 1990s [4, 5] . Consequently, the use of artemisinin derivatives and mefloquine has increased while that of chloroquine and sulfadoxine-pyrimethamine has declined. A recent in vitro study conducted in southern Vietnam indicated that the sensitivity of parasites to chloroquine was returning as a consequence of the removal of drug pressure [5] and that safe, well-tolerated, and inexpensive agents such as chloroquine and sulfadoxine-pyrimethamine might, therefore, under ap-propriate circumstances, prove suitable as partner drugs for artemisinin. If past experience with mefloquine therapy can be applied in this situation [6] , such combinations could protect against the subsequent redevelopment of resistance. We have assessed the efficacy and safety of artesunate combined with either chloroquine or sulfadoxine-pyrimethamine for the treatment of Vietnamese patients with uncomplicated falciparum malaria.
METHODS

Study sites.
Field studies were approved by the Ethics and Scientific Committee of the National Institute for Malariology, Parasitology, and Entomology (NIMPE), Hanoi, and were performed in Dac Lac and Binh Phuoc provinces. Dac Lac is a mountainous, forested central province, and the present study involved individuals belonging to the M'Nong ethnic minority, identified by active-case detection in Dac Phoi commune, Lac district. The patients recruited from the southern province of Binh Phuoc were Kinh migrant workers and their family members, who were seen at the Phu Rieng rubber plantation health center in Phuoc Long district. In both study areas, malaria is highly endemic. Malaria transmission occurs year-round, with peaks during May-June and November-December.
Patients. Informed consent was obtained from patients or their parents or guardians. Human experimentation guidelines of the authors' institutions were followed in the conduct of this research. We recruited 123 patients (57 from Dac Lac, 66 from Binh Phuoc) who were blood smear-positive for P. falciparum. All patients were aged between 4 and 65 years, did not have complications, and had a parasitemia level of 11000 parasites/ mL of whole blood. Exclusion criteria included pregnancy, concomitant illness, and prior treatment (i.e., receipt of quinine and/or an artemisinin drug within the previous 7 days, a 4-aminoquinoline within the previous 14 days, or pyrimethamine-sulfonamide within the previous 28 days [5] ). Patients with mixed infections were eligible for the study, provided that P. falciparum was the predominant pathogen.
Clinical procedures. All patients were hospitalized for у7 days. Patients were randomized to artesunate plus chloroquine therapy (group 1) or artesunate plus sulfadoxine-pyrimethamine therapy (group 2). Group 1 patients received artesunate at a dose of 4 mg/kg of body weight plus chloroquine at a dose of 15 mg base/kg orally on the first day of therapy (day 0), followed by artesunate, 2 mg/kg, plus chloroquine, 5 mg/kg, on days 1 and 2. Group 2 patients received the same artesunate regimen plus single doses of sulfadoxine, 25 mg/kg, and pyrimethamine, 1.25 mg/kg, on day 2 of therapy. Each dose was given under supervision, and patients who vomited within 1 h after admission were excluded from the study.
Follow-up was based on the World Health Organization (WHO) 28-day test [7] . Patients with persistent fever and/or parasitemia on day 7 were kept in the hospital until recovery. All patients were asked to return on days 14, 21, and 28, or at other times if they became symptomatic, for blood film screening and clinical assessment. Nonattenders were contacted by local health workers, to maximize follow-up. Patients who vomited allocated therapy or who had persistent or recurrent parasitemia received treatment with artesunate plus mefloquine. Molecular studies. Findings of field microscopy were assessed against results of P. falciparum-and Plasmodium vivaxspecific nested PCR of parasite DNA extracted from blood spots collected on day 0 and at each follow-up visit [8, 9] . Recrudescence was distinguished from reinfection using multilocus genotyping [10, 11] with nested PCR amplification of polymorphic regions of the P. falciparum genes encoding merozoite surface proteins MSP-1 (3 allelic families) and MSP-2 (2 allelic families) and glutamate-rich protein (GLURP). The presence of identical multilocus genotypes in a sample obtained on day 0 and in samples obtained during recrudescence was considered to indicate true recrudescence.
P. falciparum DNA obtained from group 1 patients was typed for the pfcrt K76T point mutation [12] using nested PCR and restriction enzyme digestion [13] . P. falciparum clones 3D7 (K76, wild type) and K1 (K76T, mutant) were included in all assays to control for mutation-specific enzyme digestion. Reactions indicating the presence of both mutant and wild type alleles were reconfirmed under stringent digestion conditions. Similar methods were used to detect the dihydrofolate reductase (pfdhfr ) mutations N51I, C59R, S108N, and I164L [14] [15] [16] . The oligonucleotide primer pairs used for multilocus genotyping and for pfcrt and pfdhfr allelic typing did not amplify the P. vivax DNA that was included as a control in all assays.
In vitro testing. The WHO standard Mark III micro-test was used to assess in vitro parasite drug sensitivity in patients with parasitemia at levels of 1000-80,000 parasites/mL. All drug plates were supplied by the WHO except for those containing artemisinin, which were produced by NIMPE under WHO guidance [5] .
Data analysis. Parasite clearance time (PCT) was defined as the time from the administration of the first dose of drug therapy to the first of 2 successive blood smears with negative results, and fever clearance time (FCT) was defined as the time required for the oral temperature to reach !37.3 ЊC for a continuous period of 124 h. Parasite resistance was categorized as RI (i.e., prompt, sustained asexual parasite clearance to day 7 of therapy but reappearance of the parasite before day 28), RII (i.e., 175% decrease in parasitemia by 48 h of therapy, but not clearance, plus persistent parasitemia on day 7), or RIII (i.e., !25% decrease in parasitemia by 48 h of therapy, plus persistent parasitemia on day 7); if none of these criteria were met, the response was categorized as sensitive (S) [7] . Response was also categorized as early treatment failure (i.e., within 3 days after starting therapy), late treatment failure (i.e., between 4 and 14 days after starting therapy), or adequate clinical and parasitological response [17] . The drug concentrations producing 50% inhibition of parasite growth in vitro (IC 50 s) were calculated using nonlinear regression [5] and are reported as geometric means and 95% CIs. MICs, the lowest drug concentrations inhibiting schizont formation, were also determined.
Statistical analysis was performed using SPSS for Windows (SPSS). Data are summarized as mean ‫ע‬ SD, geometric mean (SD range) or, for nonnormally-distributed variables, median (range). Two-sample comparisons were performed using Student's t test or Wilcoxon-Mann-Whitney tests, as appropriate. The x 2 test was used to assess differences in proportions. Comparisons of multiple means were made by analysis of variance. Logistic regression analysis was used to assess associations between variables.
RESULTS
Study sample.
Patient demographic characteristics are summarized in table 1. Patients in Dac Lac were mainly children, and those in Binh Phuoc were predominantly adults. The level of parasitemia at admission was higher in patients from Binh Phuoc, but at each site there were no significant differences between parasitemia levels in group 1 and group 2. In 24 (42%) of the patients from Dac Lac and 6 (9%) of the patients from Binh Phuoc, a mixed P. falciparum and P. vivax infection was identified by microscopy.
Clinical and parasitological response. Treatments were well-tolerated, and no patient was withdrawn from the study because of side-effects. Initial parasite clearance was prompt, but PCT was significantly shorter among patients from Dac Lac (table 1) . No RIII resistance or early treatment failure was observed. Most patients defervesced within 2 days after therapy was initiated, and FCT was similar across the 4 groups. Details of 28-day follow-up are summarized in table 2. In Dac Lac, 1 patient (from group 1) experienced treatment failure (on day 14 of therapy). Molecular analysis confirmed this treatment failure as a recrudescence but identified a further 9 patients (6 patients in group 1 and 3 patients in group 2) with cases of subclinical, submicroscopic parasitemia during follow-up. For 6 of these 9 patients, parasitemia was detected in samples obtained on day 14, and 2 of these patients remained positive at day 28. The other 3 patients with positive PCR results had parasitemia that was detected on day 28 of therapy. Molecular analysis also found 3 Dac Lac patients with pure P. vivax infections at presentation and another Dac Lac patient who had negative PCR results pretreatment.
Most Binh Phuoc patients experienced recrudescence, whether recrudescence was assessed by microscopy or PCR (table 2) . Parasite DNA analysis detected 1 reinfection. Field assessment and PCR analysis produced discordant results for 6 patients (11%). PCR showed that 1 patient had negative test results on day 0; 1 patient had a pure P. vivax infection on day 0; 1 patient had recrudescence, according to a blood smear performed on a sample obtained on day 19, although PCR revealed only P. vivax; and 2 patients had infections that were classified as RI by blood smear but were negative by PCR. Therefore, there was 1 case of subclinical treatment failure among Binh Phuoc patients compared with 9 such cases among Dac Lac patients. All 37 patients who had positive blood smear findings during follow-up were successfully treated with artesunate-mefloquine therapy.
Parasite resistance genotypes. In Dac Lac, the pfcrt K67T mutation was near fixation, with 23 of the 24 group 1 patients having a PCR result that showed they were infected with parasites carrying the mutant allele. In Binh Phuoc, parasites with pfcrt K76T were present in 60.6% of the 31 group 1 patients, but, as assessed by PCR, only 5 (33.3%) of 15 cured patients had parasites with the mutation, compared to 15 (93.8%) of 16 patients who experienced recrudescence ( ). P p .005 The N51I, C59R, and S108N dhfr mutations were at or close to fixation at both sites (with a prevalence rate of 94.3%, 100%, and 100%, respectively, for pooled group 2 patients). There were fewer infections with parasites with I164L among group 2 patients in Dac Lac (3 [12.5%] of 24 patients) than among group 2 patients in Binh Phuoc (19 of 30; 63.3%:
). P p .044 However, the presence of parasites with I164L at presentation predicted treatment failure in neither patients from Dac Lac nor patients from Binh Phuoc ( and , respec-P p .48 P p .64 tively). Among Binh Phuoc patients who experienced recrudescence, parasites with dhfr I164L were found in 29% before treatment and in 44% at their second presentation ( ). P 1 .1 Predictors of treatment failure. Logistic regression models were constructed with PCR-confirmed in vivo resistance as the dependent variable and with age, body weight, study site, baseline level of parasitemia, and presence or absence of specific mutations as independent variables. For group 1, study site ( ) and presence of pfcrt K76T ( ) were the P p .002 P p .006 only independent determinants of recrudescence. Binh Phuoc had an OR for recrudescence that was 9. In vitro drug sensitivity. Data from in vitro testing are summarized in table 3. The geometric mean IC 50 for chloroquine was similar for isolates from patients from Dac Lac and from Binh Phuoc. Of all isolates tested, 10 (12.2%) were chloroquine-resistant. Of these, 3 were from group 1 patients, 2 of whom experienced recrudescence. Geometric mean IC 50 values for pyrimethamine-sulfadoxine among isolates from patients from Binh Phuoc were higher than those in isolates from patients from Dac Lac. Among 29 group 2 patients whose isolates were tested in vitro against pyrimethamine-sulfadoxine, 9 patients with a PCR-confirmed recrudescence had isolates with higher MICs (75 nmol/L [95% CI, 75-750]) than did isolates from patients who did not experience recrudesence (25 nmol/ L [95% CI, 7.5-750];
). For artemisinin, 2 of 79 isolates P ! .05 tested (1 from Binh Phuoc and 1 from Dac Lac) showed complete inhibition at 1300 nmol/L, but recrudescence did not occur in either case.
DISCUSSION
The impetus for the present study came from evidence that the in vitro chloroquine sensitivity of P. falciparum had returned in Binh Phuoc province in the absence of drug pressure [5] . This finding, along with the reported experience with mefloquine therapy in Thailand [6] , suggested that chloroquine and sulfadoxine-pyrimethamine might be reintroduced as effective and long-lasting components of artemisinin-based combination therapy in southern Vietnam. Our results indicate that the success of this strategy depends on epidemiological factors. By WHO criteria, Dac Lac cure rates were 195% for both artesunate-chloroquine and artesunate-sulfadoxine-pyrimethamine therapy. In a recent study from the neighboring Vietnamese province of Gia Lai [18] , a 3-day course of artesunate monotherapy was given for uncomplicated falciparum malaria in a similar epidemiological setting. The 28-day recrudescence rate was 29% [18] , consistent with previous studies [1] . This suggests that chloroquine and sulfadoxine-pyrimethamine were valuable partner drugs in the present study. By contrast, most group 1 and group 2 Binh Phuoc patients exhibited RI resistance. The reasons for site-specific differences in efficacy could relate to parasite-and/or host-specific factors.
The Dac Lac patients were mostly children who had been exposed to malaria from birth and, thus, who had a degree of semi-immunity. The group of Binh Phuoc subjects was largely composed of migrants who were from urban areas where malaria is not endemic and who, therefore, had little immunity against malaria. This is likely to explain at least some of the differences in initial levels of parasitemia, PCTs, and 28-day cure rates between sites [19] . The presence of the pfcrt mutation in Dac Lac at close to fixation did not prevent high in vivo cure-rates (according to WHO criteria) but may have contributed to asymptomatic, submicroscopic, and usually transient parasitemias found by PCR in a number of patients during follow-up. Semi-immunity is likely to have played a key role in limiting and clearing these low-density recrudescences. In Binh Phuoc, the frequency of pfcrt K76T was less than in Dac Lac, and the mutation predicted group 1 treatment failure. In contrast to patients from Dac Lac, patients from Binh Phuoc who experienced recrudescences were typically symptomatic and/or blood smear-positive, highlighting the effect of immune status on clinical and parasitological features of the infection.
The same group-specific pattern of response was seen for artesunate-sulfadoxine-pyrimethamine treatment, with differences in background immunity a likely major contributing factor. The role of dhfr mutations was weaker in group 2 patients than was that of pfcrt in group 1 patients. Although we found no significant associations between dhfr mutations and clinical response in group 2, we found that I164L, the mutation most predictive of clinical failure [14, 15] , was more prevalent in Binh Phuoc than Dac Lac, and there was a trend to its selection with treatment in Binh Phuoc. In addition, available isolates from group 2 patients (mostly from Binh Phuoc) with PCRconfirmed recrudescence had significantly higher pyrimethamine-sulfadoxine IC 50 values than did those isolates obtained from patients who were cured.
We found no high-grade resistance, but 1 patient developed microscopically-detected parasitemia on day 7 of therapy, after initial clearance of parasites. This could reflect declining artesunate efficacy, because recrudescence typically occurs 114 days after short-course artemisinin monotherapy begins [1] . Because our in vitro data were collected using techniques identical to those used in a study conducted in Binh Phuoc a year previously [5] , some comparisons between the 2 studies are possible. Whereas median IC 50 values for chloroquine, mefloquine, and quinine reported for Dac Lac and Binh Phuoc in 2000 were similar to values reported for Binh Phuoc in 1999 [5] , the IC 50 95% CI for artemisinin reported in 1999 (9-24 nmol/L) did not overlap with that reported in 2000 (27-110 nmol/L). This suggests a significant short-term decrease in drug sensitivity caused by heavy use of artemisinin derivatives. Nevertheless, extrapolation of in vitro data to the in vivo situation is problematic [19] . Indeed, most of our patients who were treated with artesunate-chloroquine therapy harbored parasites with pfcrt K67T, but only 1 patient in 8 was infected with a parasite that was chloroquine-resistant in vitro [20] . This may indicate that the WHO-recommended discriminating MIC (80 nmol/L) is too high for reliable field application.
Artesunate-chloroquine and artesunate-sulfadoxine-pyrimethamine may be useful combination therapies in areas of hyperendemicity, such as Dac Lac, but their use may be inadvisable in communities with limited malarial immunity. However, in contrast to the findings of Thai studies using artesunate-mefloquine [6] , which were performed in an area of low endemicity, the selection of resistant strains may be accelerated where transmission rates are high and a drug with long half-life, such as chloroquine, is used. Reintroduction of therapy with chloroquine and sulfadoxine-pyrimethamine in conjunction with an artemisinin compound should, therefore, be accompanied by regular in vivo and in vitro testing to ensure that the effectiveness of such regimens is quantified and that the need for a change of treatment is detected early.
